Armata reports new FDA milestones for AP-SA02 ahead of planned Phase 3 startAug 12Quarterly updateArmata Pharmaceuticals, Inc.
Armata reports FDA submissions complete ahead of AP-SA02 Phase 3Jul 20Clinical readoutArmata Pharmaceuticals, Inc.
Armata Pharmaceuticals names David House chief financial officerJul 20PeopleArmata Pharmaceuticals, Inc.
Sign in